Mexico’s federal security cabinet has reported the dismantling of 1,887 clandestine drug laboratories between October 2024 and December 2025, marking a significant escalation in operations targeting synthetic drug production. The figure represents 86% of the total number of labs dismantled during the entire previous administration, suggesting a sharp increase in operational tempo under President Claudia Sheinbaum.
The operations were concentrated in states long associated with synthetic drug manufacturing—Sinaloa, Sonora, Jalisco, and Michoacán—but extended across 18 additional states. According to the government’s latest security report, the effort involved multiple federal agencies including the Army, Navy, National Guard, federal police, and the Attorney General’s Office.
Authorities seized over two million liters and more than 600,000 kilograms of chemical precursors used in drug synthesis. Equipment confiscated included 950 synthesis reactors, 646 condensers, and 185 distillers. The report also cited seizures of 318.8 tonnes of drugs and nearly 349,000 fentanyl pills. In parallel operations during the same period, authorities arrested over 40,000 individuals and confiscated more than 21,000 weapons.
Authorities now destroy labs entirely through controlled explosions to prevent reuse by criminal groups.
A notable shift in strategy was emphasized: rather than merely deactivating labs—a practice that previously allowed for reactivation—authorities now destroy them entirely through controlled explosions. This approach is intended to prevent reuse of infrastructure and equipment by criminal groups.
The government also reported enhanced intelligence gathering and customs inspections at key Pacific ports such as Manzanillo, Guaymas, and Cárdenas. These ports are known entry points for chemical precursors imported from Asia. The increased scrutiny is part of a broader effort to disrupt supply chains critical to synthetic drug production.
While the scale of enforcement is unprecedented in recent years, the broader impact remains uncertain. The report does not assess whether these actions have reduced drug availability or disrupted cartel revenues. Nor does it provide independent verification of lab destruction or detail how effectiveness is measured beyond raw numbers.
Critics argue that increased seizures may reflect improved detection rather than a decline in production. Others note that without parallel investments in social programs or economic alternatives in high-risk regions, enforcement alone may not yield lasting reductions in organized crime activity.
The Sheinbaum administration has made synthetic drug control a central pillar of its security strategy. However, as with past crackdowns, the long-term effects on trafficking routes and cartel dynamics remain to be seen.
